| Form | Liquid |
|---|
| Host Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | Interferon alpha/beta receptor 1, Cytokine receptor family 2 member 1, Cytokine receptor class-II member 1, CRF2-1, IFN-R-1, IFNAR1, IFNAR, IFN-alpha/beta receptor 1, Type I interferon receptor 1 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | P17181 |
|---|
| Background | Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.<br>• Herpes Simplex Virus 1 UL36USP Antagonizes Type I Interferon-Mediated Antiviral Innate Immunity., PMID:29997210<br/>• Structure-function study of the extracellular domain of the human type I interferon receptor (IFNAR)-1 subunit., PMID:10841076<br/>• The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation., PMID:11096454<br/>• ITAM-coupled receptors inhibit IFNAR signaling and alter macrophage responses to TLR4 and Listeria monocytogenes., PMID:22368279<br/>• Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells., PMID:24460759<br/>• The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells., PMID:14980077<br/>• N-glycosylation of murine IFN-beta in a putative receptor-binding region., PMID:16734561<br/>• Expression and function of RIG-I in oral keratinocytes and fibroblasts., PMID:25359319<br/>• Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis., PMID:21832278<br/>• Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon., PMID:31390156<br/> |
|---|
| Alternative Names | MDX-1333, MEDI-546, 1326232-46-5 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|